Compare ASLE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASLE | DCTH |
|---|---|---|
| Founded | 2008 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 311.7M |
| IPO Year | 2018 | 2015 |
| Metric | ASLE | DCTH |
|---|---|---|
| Price | $6.83 | $10.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $22.00 |
| AVG Volume (30 Days) | 205.7K | ★ 264.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.64 | ★ 107.53 |
| EPS | ★ 0.18 | 0.07 |
| Revenue | ★ $335,286,000.00 | N/A |
| Revenue This Year | $23.41 | $24.54 |
| Revenue Next Year | $6.80 | $33.15 |
| P/E Ratio | ★ $38.00 | $155.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $8.12 |
| 52 Week High | $9.08 | $18.23 |
| Indicator | ASLE | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 57.05 |
| Support Level | $5.92 | $10.50 |
| Resistance Level | $7.16 | $10.75 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 57.25 | 62.91 |
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.